Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.

Thrombopoietin (TPO) is the physiologic Mpl-ligand regulating platelet production. Pegylated human recombinant megakaryocyte growth and development factor (PEG-rHuMGDF), a truncated polypeptide Mpl-ligand derivitized with poly-(ethylene glycol), induces megakaryocyte endoreduplication and proliferation in vitro and in vivo. In the present study, the dose-response effects of PEG-rHuMGDF on pharmacokinetics, megakaryocytopoiesis, platelet production, and platelet function were characterized for dosing 0.05, 0.10, 0.50, or 2.5 micrograms/kg/d in 22 baboons for 28 days. Daily subcutaneous injections of PEG-rHuMGDF produced linear log-dose responses in (1) steady-state trough plasma levels of PEG-HuMGDF (P < 10(-3)); (2) marrow megakaryocyte volume (P < 10(-3)), ploidy (P < 10(-4)), and number (P < .01); and (3) peripheral platelet concentrations (P < 10(-4)) and platelet mass turnover (P < 10(-3)). Platelet morphology, life span, and recovery were normal, and peripheral leukocyte, neutrophil, and erythrocyte counts were not significantly affected by PEG-rHuMGDF (P > .1 in all cases). PEG-rHuMGDF at 0.5 micrograms/kg/d produced similar blood concentrations of Mpl-ligand and platelets as 10 times the dose of rHu-MGDF (5.0 micrograms/kg/d), reflecting the extended plasma half-life achieved through pegylation. Whereas PEG-rHuMGDF did not induce platelet aggregation in vitro, platelet aggregatory responsiveness induced by thrombin receptor agonist peptide (TRAP1-6) and collagen was transiently enhanced ex vivo during the initial few days of PEG-rHuMGDF administration. However, adenosine diphosphate (ADP)-induced platelet aggregation was not enhanced ex vivo by PEG-rHuMGDF therapy. 111In-platelet deposition on segments of homologous endarterectomized aorta (EA) and vascular graft (VG) interposed in arteriovenous femoral shunts increased in direct proportion to the circulating platelet concentration (P < 10(-4) for both EA and VG); 125l-fibrin accumulation was not affected by PEG-rHuMGDF-induced increases in peripheral platelet counts. Changes in platelet production and function produced by PEG-rHuMGDF returned to baseline within 2 weeks after discontinuing treatment. Thus, in nonhuman primates, PEG-rHuMGDF increases platelet production in a linear log-dose-dependent manner by stimulating megakaryocyte endoreduplication and new megakaryocyte formation from marrow hematopoietic progenitors. These findings suggest that appropriate dosing of PEG-rHuMGDF therapy during periods of chemotherapy-induced marrow suppression may maintain hemostatic concentrations of peripheral platelets without increasing the risk of thrombosis.

[1]  A. Tefferi,et al.  The effects of anagrelide on human megakaryocytopoiesis , 1997, British journal of haematology.

[2]  S. Hanson,et al.  Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates. , 1996, Blood.

[3]  K. Kaushansky.  Thrombopoietin the primary regulator of platelet production. , 1995, Trends in endocrinology and metabolism: TEM.

[4]  H. Lu,et al.  Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. , 1995, Blood.

[5]  A. Iwamatsu,et al.  Purification and characterization of thrombopoietin. , 1995, Journal of biochemistry.

[6]  T. Boone,et al.  Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. , 1995, Blood.

[7]  T. Kato,et al.  Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia. , 1995, The Journal of clinical investigation.

[8]  J. Shutter,et al.  Cloning and Characterization of the Human Megakaryocyte Growth and Development Factor (MGDF) Gene (*) , 1995, The Journal of Biological Chemistry.

[9]  D. Beeler,et al.  The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Rosenberg,et al.  Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. , 1994, Blood.

[11]  M. C. Hu,et al.  Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor MpI , 1994, Cell.

[12]  V. Broudy,et al.  Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin , 1994, Nature.

[13]  William Vainchenker,et al.  c-Mpl ligand is a humoral regulator of megakaryocytopoiesis , 1994, Nature.

[14]  D. Goeddel,et al.  Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand , 1994, Nature.

[15]  Scott R. Presnell,et al.  Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo , 1994, Nature.

[16]  S. Hanson,et al.  Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. , 1994, Blood.

[17]  R. Mcmillan,et al.  Bernard‐Soulier syndrome: quantitative characterization of megakaryocytes and platelets by flow cytometric and platelet kinetic measurements , 1994, European journal of haematology.

[18]  A. Nurden,et al.  Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups , 1993 .

[19]  A. Lumsden,et al.  Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH2Cl in baboons. , 1993, Blood.

[20]  P. Teirstein,et al.  Activation of platelets in blood perfusing angioplasty-damaged coronary arteries. Flow cytometric detection. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[21]  C. Creutz.  The annexins and exocytosis. , 1992, Science.

[22]  P. Comfurius,et al.  Platelet procoagulant activity and microvesicle formation. Its putative role in hemostasis and thrombosis. , 1992, Biochimica et biophysica acta.

[23]  S. Hanson,et al.  Antithrombotic effects of synthetic peptides targeting various functional domains of thrombin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Hanson,et al.  Autologous platelet kinetics in patients with severe thrombocytopenia: discrimination between disorders of production and destruction. , 1991, The Journal of laboratory and clinical medicine.

[25]  B. Eaton,et al.  BK virus and JC virus shed during pregnancy have predominantly archetypal regulatory regions , 1991, Journal of virology.

[26]  S. Hanson,et al.  Experimental arterial thrombosis in nonhuman primates. , 1991, Circulation.

[27]  S. Nakamura,et al.  Supernatants of acquired immunodeficiency syndrome-related Kaposi's sarcoma cells induce endothelial cell chemotaxis and invasiveness. , 1991, Cancer research.

[28]  S. Hanson,et al.  Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. , 1991, Blood.

[29]  J. Tait,et al.  Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. , 1990, The Journal of biological chemistry.

[30]  A. Frelinger,et al.  Selective inhibition of integrin function by antibodies specific for ligand-occupied receptor conformers. , 1990, The Journal of biological chemistry.

[31]  W. Vainchenker,et al.  Human megakaryocytopoiesis: in vitro regulation and characterization of megakaryocytic precursor cells by differentiation markers. , 1988, Blood reviews.

[32]  L. Harker,et al.  Flow cytometric analysis of normal human megakaryocytes. , 1988, Blood.

[33]  S. Hanson,et al.  Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J C Bailar,et al.  Guidelines for statistical reporting in articles for medical journals. Amplifications and explanations. , 1988, Annals of internal medicine.

[35]  S. Hanson,et al.  Selective decrease in platelet dense granule adenine nucleotides during recovery from acute experimental thrombocytopenia and ensuing thrombocytosis in baboons , 1988, British journal of haematology.

[36]  M. Hirata,et al.  Structure and expression of cDNA for an inhibitor of blood coagulation isolated from human placenta: a new lipocortin-like protein. , 1987, Journal of biochemistry.

[37]  K. Fujikawa,et al.  Human placental anticoagulant protein: isolation and characterization. , 1987, Biochemistry.

[38]  L. Corash,et al.  Regulation of thrombopoiesis: effects of the degree of thrombocytopenia on megakaryocyte ploidy and platelet volume. , 1987, Blood.

[39]  R. Rosenberg,et al.  Purification and properties of a megakaryocyte stimulatory factor present both in the serum-free conditioned medium of human embryonic kidney cells and in thrombocytopenic plasma. , 1987, The Journal of biological chemistry.

[40]  R. Rosenberg,et al.  In vitro stimulation of megakaryocyte maturation by megakaryocyte stimulatory factor. , 1987, The Journal of biological chemistry.

[41]  A. Look,et al.  Inverse relationship between megakaryocyte buoyant density and maturity , 1986, British journal of haematology.

[42]  S. Hanson,et al.  The relation of platelet density to platelet age: survival of low- and high-density 111indium-labeled platelets in baboons. , 1986, Blood.

[43]  S. Hanson,et al.  Platelet Interactions with Dacron Vascular Grafts: A Model of Acute Thrombosis in Baboons , 1985, Arteriosclerosis.

[44]  E. Mazur,et al.  Megakaryocyte colony stimulating factor in sera from aplastic dogs partial purification characterization and determination of hematopoietic cell lineage specificity , 1985 .

[45]  M. Shuman,et al.  A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation , 1985, The Journal of cell biology.

[46]  D. Slater,et al.  The relationship between platelet and megakaryocyte volumes. , 1982, Thrombosis research.

[47]  L. J. Williams,et al.  Mean platelet volume. The inverse relation of platelet size and count in normal subjects, and an artifact of other particles. , 1981, American journal of clinical pathology.

[48]  S. Hanson,et al.  Experimental Arterial Thromboembolism in Baboons: Mechanism, Quantitation and Pharmacologic Prevention , 1979, Thrombosis and Haemostasis.

[49]  Harker La,et al.  Thrombocytopenia: mechanisms and management of defects in platelet production. , 1978, Clinics in haematology.

[50]  J. Cook,et al.  Kinetics of the formed elements of human blood. , 1977, Blood.

[51]  S. Jamieson,et al.  A Relationship between Platelet Volume and Platelet Number , 1974, Thrombosis and Haemostasis.

[52]  J. Levin,et al.  Thrombopoietic activity of fractions of rabbit plasma: studies in rabbits and mice. , 1974, The Journal of laboratory and clinical medicine.

[53]  R. Aster,et al.  Platelet Kinetics: radioisotopic, cytological, mathematical and clinical aspects , 1972 .

[54]  L. Harker.  Regulation of thrombopoiesis. , 1970, The American journal of physiology.

[55]  L. Harker,et al.  Thrombokinetics in man. , 1969, The Journal of clinical investigation.

[56]  L. Harker,et al.  Kinetics of thrombopoiesis. , 1968, The Journal of clinical investigation.

[57]  T. McDonald,et al.  Stimulation of Platelet Production by Serum of Platelet-Depleted Rats , 1961, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[58]  M. Hokom,et al.  Recombinant human megakaryocyte growth and development factor (rhumgdf), a ligand for c‐mpl, produces functional human platelets in vitro , 1995, Stem cells.

[59]  H. Lu,et al.  Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. , 1994, Cell.

[60]  S. Hanson,et al.  Platelet factors predisposing to arterial thrombosis. , 1994, Bailliere's Clinical Haematology.

[61]  S. Hanson,et al.  Origins and Significance of Platelet Heterogeneity in a Non-human Primate Model , 1990 .

[62]  L. Harker,et al.  Flow cytometric analysis of megakaryocytes from patients with abnormal platelet counts. , 1989, Blood.

[63]  S. Hanson,et al.  Effects of monoclonal antibodies against the platelet glycoprotein IIb/IIIa complex on thrombosis and hemostasis in the baboon. , 1988, The Journal of clinical investigation.

[64]  A. Gewirtz.  Human megakaryocytopoiesis. , 1986, Seminars in hematology.

[65]  W. Vainchenker,et al.  Expression of platelet proteins during the in vitro and in vivo differentiation of megakaryocytes and morphological aspects of their maturation. , 1986, Seminars in hematology.

[66]  Howard M. Shapiro,et al.  Practical Flow Cytometry , 1985 .

[67]  S. Hanson,et al.  Pharmacologic modification of acute vascular graft thrombosis. , 1982, Scanning electron microscopy.

[68]  L. Harker,et al.  Thrombocytopenia: mechanisms and management of defects in platelet production. , 1978, Clinics in haematology.

[69]  K. Jacobsson.  I. Studies on the determination of fibrinogen in human blood plasma. II. Studies on the trypsin and plasmin inhibitors in human blood serum. , 1955, Scandinavian journal of clinical and laboratory investigation.